Bilastuff M 4 Tablet contains Bilastine 20 mg and Montelukast 4 mg, a combination therapy for managing allergies and respiratory conditions.
Bilastine is a non-sedating antihistamine that blocks H1 receptors, reducing sneezing, itching, and watery eyes, while Montelukast is a leukotriene receptor antagonist that reduces airway inflammation, nasal congestion, and bronchial hyperreactivity. Together, they provide comprehensive relief from allergic rhinitis, seasonal allergies, and asthma-related symptoms.
Clinically, Bilastuff M 4 Tablet is ideal for patients suffering from chronic or seasonal allergies, asthma triggers, or upper respiratory discomfort, ensuring better symptom control, patient comfort, and improved quality of life.
From a business perspective, Bilastuff M 4 Tablet strengthens the allergy and respiratory therapy segment, widely prescribed in ENT clinics, respiratory clinics, and hospitals, offering steady demand, repeat prescriptions, and trusted clinical efficacy, making it a high-value addition for pharma partners.